Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
about
Eph receptors and ephrin ligands: important players in angiogenesis and tumor angiogenesisEmerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderEphs and Ephrins in malignant gliomasProtein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylationSignificance of ER-Src axis in hormonal therapy resistanceLithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activationLigand-dependent activation of EphA4 signaling regulates the proteolysis of amyloid precursor protein through a Lyn-mediated pathway.Anti-EphA2 Antibodies with Distinct In Vitro Properties Have Equal In Vivo Efficacy in Pancreatic Cancer.Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.Engineering of monobody conjugates for human EphA2-specific optical imaging.Eph receptors and ephrins in cancer: bidirectional signalling and beyond.SRC: a century of science brought to the clinic.The Achilles' heel of senescent cells: from transcriptome to senolytic drugs.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.Human cataract mutations in EPHA2 SAM domain alter receptor stability and function.Emerging strategies for EphA2 receptor targeting for cancer therapeutics.Predictive biomarkers for dasatinib treatment in melanoma.Eph receptors and ephrins as targets for cancer therapy.EphrinA2 receptor (EphA2) is an invasion and intracellular signaling receptor for Chlamydia trachomatis.Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studiesDesign and Characterization of Novel EphA2 Agonists for Targeted Delivery of Chemotherapy to Cancer Cells.Molecular targeted approaches for treatment of pancreatic cancer.Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.Proteolysis of EphA2 Converts It from a Tumor Suppressor to an OncoproteinApplication of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma.Targeting genomic alterations in squamous cell lung cancer.Eph receptor signaling and ephrinsDasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.Novel agents for the treatment of adenocarcinoma of the pancreas.Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.Targeting Eph receptors with peptides and small molecules: progress and challenges.The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.Therapeutic targeting of EPH receptors and their ligands.Predicting resistance by selection of signaling pathways.Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL.Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors.Design, Synthesis, and Evaluation of Dasatinib-Amino Acid and Dasatinib-Fatty Acid Conjugates as Protein Tyrosine Kinase Inhibitors.Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.
P2860
Q21328694-896DB749-DEB5-40DA-8814-EB37398475F1Q26859114-CF2A682F-5431-4E60-851D-C4A944A5558EQ27015780-4FA6F12F-50D2-45DD-9B4B-B646E0DB08CAQ28116202-69CC9E4E-4241-4FC1-B420-EF1531545631Q28301805-1B5493F3-B183-43BE-8EE5-16A47DEC4723Q28477562-0FB3962B-F30E-4315-A398-DBEBE7045A42Q31814817-DB892A4C-D7DD-4C62-91F2-2899B1D75F57Q33529392-F5DA4C82-53AA-40EE-A453-04232FFEEDA6Q33848124-8A20C2E3-FF6D-4305-BF5B-F7ECE816F267Q33884270-C11AA98F-BED1-4CFE-8BD5-A6302D4EF01AQ34021365-4750C20F-66C5-4B7E-ADE4-FCACCBE0A151Q34041298-08492425-B624-49A9-9B12-B2FF1CC8B371Q34043405-91BA5D19-CA55-4BD5-8144-37B0FE6EDCABQ34121339-8241EAC4-08CC-4DEB-A9A0-BC78DA866555Q34257256-D3B3581B-7924-4654-B21A-80D89E3F40DEQ34263351-3AF678F2-CEBB-47E5-9FD6-6B0107854EDDQ34469271-0FBD305D-B742-4C5A-B307-A741342D617AQ34781153-B608B82C-B523-4D04-9D33-9DDBC54BBB66Q35370195-F76BFEC7-9DC1-45FD-9CE1-36FF4A3F70C0Q35533099-08EC52C4-B5EF-4D29-9996-F4BBF970D4CBQ35539318-D4C01C57-B4FB-42CE-877C-F45D245B5EA0Q35889278-553CF99B-9DEF-440F-858E-D5FBEC042D97Q36174910-B520DCF7-E2CE-4CCC-A591-AF0C201FB1AEQ36253834-83D6FD01-288F-41A7-B2B4-1AB4489A1B60Q36380708-A5B4B297-A0BB-4D77-9869-ABA0E745C909Q36855805-FCBBAA96-0D97-43C3-99A1-31932C6FE0F4Q37068767-0BA38860-2C02-4240-93FB-71D895AB3559Q37122330-0DFE2FDF-1C0D-41C7-9F51-7D423B76BDA6Q37613072-07B326A4-486A-483A-9696-38F9A12BE5D9Q37614590-1AAEE94E-4A15-40EF-8E6C-CFE8ECFF7DF7Q37625252-DCB0F70B-C445-47D4-B5B4-C8DC84FD3790Q37684642-399ADB25-38A1-470A-A6AD-D069EAFAFA49Q37951723-50F1C500-F1DB-42FE-8935-0F7CDA9D5B0AQ38128723-65479AE6-D2AA-4FD3-8134-EEA0D5C65162Q38174793-35D5FCD1-F78B-4C74-B906-58A43F7CFF9EQ38390126-1B724DDD-CC15-4A7C-9882-600F05B24F82Q38694303-742E55AD-60CC-423B-BEA1-A8ACD5D5E3D2Q38702282-D2CB8F23-D15B-4EA1-B0B0-9AB7A59ECEF4Q38729630-583E1C44-7666-4849-8872-31C2E167177FQ38818048-09ADA097-E76C-457C-A3D4-84CBC121FD05
P2860
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Effects of dasatinib on EphA2 ...... gnalling in pancreatic cancer.
@en
type
label
Effects of dasatinib on EphA2 ...... gnalling in pancreatic cancer.
@en
prefLabel
Effects of dasatinib on EphA2 ...... gnalling in pancreatic cancer.
@en
P2093
P2860
P356
P1476
Effects of dasatinib on EphA2 ...... ignalling in pancreatic cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6604676
P407
P50
P577
2008-09-16T00:00:00Z